Central Trust Company’s Northwest Biotherapeutics, Inc. Common stock NWBO Stock Holding History

Central Trust Company’s Portfolio NWBO Stock Details NWBO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q3	–	Sell	-1,000	Closed	–	–	1243
2016 Q2	$0	Hold	1,000	–	–	﹤0.01%	1212
2016 Q1	$1K	Hold	1,000	–	–	﹤0.01%	1107
2015 Q4	$3K	Hold	1,000	–	–	﹤0.01%	1118
2015 Q3	$6K	Hold	1,000	–	–	﹤0.01%	1074
2015 Q2	$10K	Hold	1,000	–	–	﹤0.01%	1018
2015 Q1	$7K	Hold	1,000	–	–	﹤0.01%	1054
2014 Q4	$5K	Hold	1,000	–	–	﹤0.01%	1095
2014 Q3	$5K	Sell	1,000 -1,500	-60%	-$9.22K	﹤0.01%	1087
2014 Q2	$17K	Sell	2,500 -1,000	-29%	-$6.37K	﹤0.01%	885
2014 Q1	$25K	Buy	+3,500	New	+$20.7K	﹤0.01%	802

Other funds holding NWBO

WIM

Woodford Investment Management London, United Kingdom $310M AUM 17.41% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Creative Planning Overland Park, Kansas $147B AUM 18.73% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

CDH

Charles D. Hyman $1.79B AUM 17.18% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Central Trust Company's NWBO Position: Q3 2016 in Review

Central Trust Company sold out of Northwest Biotherapeutics, Inc. Common stock (NWBO) in Q3 2016, closing a stake of 1,000 shares.

Central Trust Company first reported a position in NWBO in Q1 2014 and held it in 10 quarters. The position peaked at $25K in Q1 2014. 54 funds tracked by Wall St. Rank hold NWBO as of Q3 2016.

Central Trust Company reported no remaining Northwest Biotherapeutics, Inc. Common stock position as of Q3 2016 after selling out during the quarter.
Central Trust Company sold 1,000 Northwest Biotherapeutics, Inc. Common stock shares in Q3 2016.
Central Trust Company first reported a position in Northwest Biotherapeutics, Inc. Common stock in Q1 2014 and held it in 10 quarters.
Central Trust Company's Northwest Biotherapeutics, Inc. Common stock position peaked at $25K in Q1 2014.
54 funds tracked by Wall St. Rank held Northwest Biotherapeutics, Inc. Common stock as of Q3 2016.

Based on Central Trust Company's 13F filing for Q3 2016, filed 24 Oct 2016.